Fig. 5.

Administration of exendin-4 into the nucleus accumbens shell attenuates oxycodone and cue priming-induced reinstatement of drug-seeking behavior. Microinjection sites in rats pretreated with vehicle and exendin-4 in the shell prior to reinstatement test sessions (a). Total active lever responses (b) and total infusions (c) were attenuated in rats (n = 16/treatment) pretreated with 0.005 and 0.05 µg exendin-4 versus vehicle in the shell (*p < 0.05, Bonferroni). Exendin-4 infusions in the shell had no effect on cumulative chow intake (d) or body weight change (f) in rats during abstinence (n = 11/treatment). In contrast, 24-h water intake (e) was significantly decreased in rats pretreated with 0.05 µg exendin-4 versus vehicle in the shell (*p < 0.05, Bonferroni)